Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald

Oric Pharmaceuticals (ORIC) presented a Phase 1 dose optimization update for rinzimetostat combined with darolutamide in mCRPC, alongside details of the upcoming Phase 3 trial, Cantor tells investors in a research note. Efficacy appears comparable to competitor mevrometostat from Pfizer (PFE), with Rinzi showing a potentially better safety profile, the firm says, adding thatshares are down 20%-25%, partly due to early treatment discontinuations shown in the swimmer plot, which are similar to mevrometostat’s experience. Cantor has an Overweight rating on Oric shares.